Targeting MYCN in Molecularly Defined Malignant Brain Tumors

Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis

(2020) Jue Jiang et al.   CANCER CELL

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

(2020) William M. Pardridge   Frontiers in Aging Neuroscience

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review

(2020) Cyrillo G. Brahm et al.   Cancers

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

(2020) Laura K. Donovan et al.   NATURE MEDICINE

Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma

(2020) Alexandra Garancher et al.   NATURE NEUROSCIENCE

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation

(2020) Omer Gilan et al.   SCIENCE

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

(2020) Sung-Jen Wei et al.   Cell Death & Disease

Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes

(2020) Matthew Clarke et al.   Cancer Discovery

WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?

(2020) Anthony P. Y. Liu et al.   ACTA NEUROPATHOLOGICA

Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer

(2020) P. Jake Slavish et al.   CANCER RESEARCH

Tumor Treating Fields in the Management of Patients with Malignant Gliomas

(2020) Ashley P. Ghiaseddin et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood

(2020) Radek Frič et al.   Scientific Reports

CAR T Cell Therapy for Pediatric Brain Tumors

(2020) John D. Patterson et al.   Frontiers in Oncology

Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers

(2020) Hoon Kim et al.   NATURE GENETICS

Medulloblastoma

(2019) Paul A. Northcott et al.   Nature Reviews Disease Primers

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

(2019) Marie-Eve Beaulieu et al.   Science Translational Medicine

Challenges to curing primary brain tumours

(2019) Kenneth Aldape et al.   Nature Reviews Clinical Oncology

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

(2019) Cyril Neftel et al.   CELL

Targeting mTOR for cancer therapy

(2019) Hui Hua et al.   Journal of Hematology & Oncology

MYCN amplification drives an aggressive form of spinal ependymoma

(2019) David R. Ghasemi et al.   ACTA NEUROPATHOLOGICA

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

(2019) Huiying Han et al.   CANCER CELL

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells

(2019) Matko Čančer et al.   Cell Death & Disease

Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study

(2019) Bryan K. Li et al.   ACTA NEUROPATHOLOGICA

Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy

(2019) Matko Čančer et al.   Cell Stem Cell

Small Molecule Driven Stabilization of Promoter G-Quadruplexes and Transcriptional Regulation of c-MYC

(2018) Tania Das et al.   BIOCONJUGATE CHEMISTRY

Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models

(2018) Mari Kogiso et al.   CLINICAL CANCER RESEARCH

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries

(2018) Lindsey M. Hoffman et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex

(2018) Ming-Hao Hu et al.   JOURNAL OF MEDICINAL CHEMISTRY

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

DNA methylation-based classification of central nervous system tumours

(2018) David Capper et al.   NATURE

Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma

(2018) Ana C. deCarvalho et al.   NATURE GENETICS

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

(2018) Sara Bolin et al.   ONCOGENE

Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles

(2018) Fred C. Lam et al.   Nature Communications

A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation

(2018) Alina Castell et al.   Scientific Reports

Current Strategies for Brain Drug Delivery

(2018) Xiaowei Dong   Theranostics

Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo

(2018) Irina Alimova et al.   INTERNATIONAL JOURNAL OF CANCER

Dendritic cell vaccines for high-grade gliomas

(2018) Matthew Eagles et al.   Therapeutics and Clinical Risk Management

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma

(2018) Joshua Felgenhauer et al.   NEOPLASIA

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

(2018) John Hines et al.   CANCER RESEARCH

PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048

(2018) Stewart Goldman et al.   NEURO-ONCOLOGY

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma

(2018) Øyvind H. Hald et al.   ONCOGENE

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex

(2018) David R. Calabrese et al.   Nature Communications

Cancer: Keeping it real to kill glioblastoma

(2017) Paul A. Northcott   NATURE

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity

(2017) Kristen M. Turner et al.   NATURE

Spatial heterogeneity in medulloblastoma

(2017) A Sorana Morrissy et al.   NATURE GENETICS

High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells

(2017) Patrícia Benites Gonçalves da Silva et al.   Oncotarget

Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor

(2017) Giles W. Robinson et al.   Oncotarget

Targeting Cancer Cells with BET Bromodomain Inhibitors

(2017) Yali Xu et al.   Cold Spring Harbor Perspectives in Medicine

Small-Molecule PROTACS: New Approaches to Protein Degradation

(2016) Momar Toure et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes

(2016) Pascal D. Johann et al.   CANCER CELL

The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity

(2016) BaoHan T. Vo et al.   CANCER CELL

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

(2016) Lori S. Hart et al.   CLINICAL CANCER RESEARCH

A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

(2016) Daniel Dauch et al.   NATURE MEDICINE

Epidemiology of Brain Tumors

(2016) Katharine A. McNeill   NEUROLOGIC CLINICS

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

(2016) Lynsey Vaughan et al.   Oncotarget

Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007

(2016) Kerstin Bartelheim et al.   Cancer Medicine

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

(2015) Rebecca M. Hill et al.   CANCER CELL

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas

(2015) Yoshiki Kaneko et al.   CANCER SCIENCE

Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape

(2015) Amar Gajjar et al.   JOURNAL OF CLINICAL ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Akt-mediated phosphorylation of Oct4 is associated with the proliferation of stem-like cancer cells

(2015) QING-WEI ZHAO et al.   ONCOLOGY REPORTS

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents

(2015) Pu Wang et al.   Cell Reports

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer

(2015) Tene Aneka Cage et al.   Frontiers in Oncology

Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma

(2015) Zai Ahmad et al.   PLoS One

Drugging MYCN through an Allosteric Transition in Aurora Kinase A

(2014) William Clay Gustafson et al.   CANCER CELL

Cytogenetic Prognostication Within Medulloblastoma Subgroups

(2014) David J.H. Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploration of the selective recognition of the G-quadruplex in the N-myc oncogene by electrospray ionization mass spectrometry

(2014) Fangyuan Li et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

(2014) Daniela Annibali et al.   Nature Communications

NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas

(2014) Yusuke Suenaga et al.   PLoS Genetics

Solution equilibria of cytosine- and guanine-rich sequences near the promoter region of the n-myc gene that contain stable hairpins within lateral loops

(2013) Sanae Benabou et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

(2013) Markus Brockmann et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Targeting a c-MYC G-quadruplex DNA with a fragment library

(2013) Hamid R. Nasiri et al.   CHEMICAL COMMUNICATIONS

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

(2013) Katarzyna Kotulska et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome

(2013) Yazmin Odia et al.   JOURNAL OF NEURO-ONCOLOGY

BRD4 Coordinates Recruitment of Pause Release Factor P-TEFb and the Pausing Complex NELF/DSIF To Regulate Transcription Elongation of Interferon-Stimulated Genes

(2013) M. C. Patel et al.   MOLECULAR AND CELLULAR BIOLOGY

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

(2013)   NATURE GENETICS

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

(2013) Lynn Bjerke et al.   Cancer Discovery

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC

(2012) Fredrik J. Swartling et al.   CANCER CELL

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

(2012) Panagis Filippakopoulos et al.   CELL

Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas

(2012) Norman L. Lehman et al.   CELL CYCLE

Reciprocal Regulation of Akt and Oct4 Promotes the Self-Renewal and Survival of Embryonal Carcinoma Cells

(2012) Yuanji Lin et al.   MOLECULAR CELL

Paediatric and adult malignant glioma: close relatives or distant cousins?

(2012) Chris Jones et al.   Nature Reviews Clinical Oncology

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Demonstration that Drug-targeted Down-regulation of MYC in Non-Hodgkins Lymphoma Is Directly Mediated through the Promoter G-quadruplex

(2011) Robert V. Brown et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

(2011) K C Goh et al.   LEUKEMIA

c-MYC promoter G-quadruplex formed at the 5′-end of NHE III 1 element: insights into biological relevance and parallel-stranded G-quadruplex stability

(2011) Raveendra I. Mathad et al.   NUCLEIC ACIDS RESEARCH

The C-Terminus of Nucleolin Promotes the Formation of the c-MYCG-Quadruplex and Inhibits c-MYCPromoter Activity

(2010) Verónica González et al.   BIOCHEMISTRY

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

(2010) J. den Hollander et al.   BLOOD

Differential expression of centrosomal proteins at different stages of human glioma

(2010) Joon-Khim Loh et al.   BMC CANCER

c-Myc Regulates Transcriptional Pause Release

(2010) Peter B. Rahl et al.   CELL

Pleiotropic role for MYCN in medulloblastoma

(2010) F. J. Swartling et al.   GENES & DEVELOPMENT

Aurora kinase A as a rational target for therapy in glioblastoma

(2010) Valerie N. Barton et al.   Journal of Neurosurgery-Pediatrics

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells

(2009) André O von Bueren et al.   BMC CANCER

Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma

(2009) Tobias Otto et al.   CANCER CELL

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

(2009) D. Drygin et al.   CANCER RESEARCH

Identification ofN,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor

(2009) Maria Gabriella Brasca et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts

(2009) J. Graeme Hodgson et al.   NEURO-ONCOLOGY

Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features

(2009) Vassilis Samaras et al.   PATHOLOGY RESEARCH AND PRACTICE

mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells

(2009) J. Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation

(2009) P. Hydbring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c -MYC amplification and expression in astrocytic tumors

(2008) Mário Henrique Faria et al.   ACTA NEUROPATHOLOGICA

Malignant Gliomas with Primitive Neuroectodermal Tumor-like Components: A Clinicopathologic and Genetic Study of 53 Cases

(2008) Arie Perry et al.   BRAIN PATHOLOGY

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

(2008) Frank Westermann et al.   GENOME BIOLOGY